Baller Alert
  • Home
    • News
    • Entertainment
    • The Baller Alert Show
    • Baller Alert Lists
    • Baller Alert Exclusives
    • Let Me Liv
    • Ballerific Music
    • That’s Baller
    • Fashion
    • Metaverse
    • Tech
    • Lifestyle
    • Sports
    • Op-Ed
    • Travel
    • Health
  • EVENTS
  • Videos
  • Shop
  • About
  • Political News
  • en español
No Result
View All Result
  • Home
    • News
    • Entertainment
    • The Baller Alert Show
    • Baller Alert Lists
    • Baller Alert Exclusives
    • Let Me Liv
    • Ballerific Music
    • That’s Baller
    • Fashion
    • Metaverse
    • Tech
    • Lifestyle
    • Sports
    • Op-Ed
    • Travel
    • Health
  • EVENTS
  • Videos
  • Shop
  • About
  • Political News
  • en español
No Result
View All Result
Baller Alert
No Result
View All Result

The FDA Has Approved The First Alzheimer’s Treatment To Treat Cognitive Decline

by RaquelHarris
June 7, 2021
Reading Time: 1 min read
0
First Alzheimer's Drug to Slow Disease Gets Full FDA Approval

Alzheimers Concept - a conceptual look at Alzheimers disease, and some of the problems it brings.

Share on FacebookShare on Twitter

The FDA has approved the first Alzheimer’s treatment to slow down cognitive decline. Critics are concerned the new drug doesn’t have enough evidence to guarantee it actually works.

Aducanumab is now the first Alzheimer’s drug to be cleared and approved by the United States Food and Drug Administration (FDA). The Washington Post reports the drug will change the course of the disease by slowing down the deterioration of brain function. The last time an Alzheimer’s drug was approved was in 2003.

The drug was manufactured by the biotech company Biogen; the FDA directs the company to test the drug. Biogen will put together a post-approval study to confirm the drug actually works.

The Washington Post reports the required portion of the program is called accelerated approval, and it “is designed to allow for earlier approval of drugs that treat serious or life-threatening conditions” so that the U.S. health industry can fix urgent or growing medical issues. Laurie McGinley of the newspaper writes.

Scientists, physicians, and health experts will track how well the medication reduces the amount of amyloid plaque found in the brain. In a statement, Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said clinical trials showed the decline in plaque “is expected to lead to a reduction in the clinical decline of this devastating form of dementia.”

However, critics say the way the drug has been handled between the FDA and Biogen is inappropriate. On Monday, Public Citizen said, “the close collaboration between the FDA and Biogen before and after the submission of the company’s marketing application for aducanumab dangerously compromised the integrity of the agency’s review.”

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on X (Opens in new window) X
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on Pinterest (Opens in new window) Pinterest

Like this:

Like Loading...

Discover more from Baller Alert

Subscribe to get the latest posts sent to your email.

Tags: Alzheimer’sFDA

Related Posts

Trump’s “One Big Beautiful Bill” Narrowly Passes Senate, Heads to House
News

Trump’s New Bill Slashes Medicaid—Millions Will Lose Coverage and Clinics Will Close

July 1, 2025

As Republicans hustle to pass Donald Trump’s “One Big Beautiful Bill” by his self-imposed July 4 deadline, a major concern...

Trump’s “One Big Beautiful Bill” Narrowly Passes Senate, Heads to House
News

GOP Just Slid Trump’s $3 Trillion Tax Bill Through the Senate—Here’s Who Wins and Who Loses

July 1, 2025

After a marathon 24-hour debate and high-stakes political wrangling, Senate Republicans have pushed Donald Trump’s “One Big Beautiful Bill Act”...

Rapper Cash Out’s Sex Trafficking Trial Reveals Graphic Abuse, Coercion, and His Mother’s Alleged Role
News

Cash Out and His Mother Accused of Witness Tampering in RICO Case

July 1, 2025

Cash Out’s legal case just took another turn. The Atlanta rapper, whose real name is John Michael Gibson, is now...

Remy Ma refutes allegations
News

Remy Ma Allegedly Detained Following Heated Courthouse Clash in Son’s Murder Case [Video]

July 1, 2025

Remy Ma found herself in cuffs after a tense and emotional situation played out outside a Queens courthouse. The rapper...

Next Post
T MOBILE

Former T-Mobile Sales Rep Sues Company After HR Member Asked Her About OnlyFans Account

Leave a ReplyCancel reply

Baller News

Subscribe To Our Newsletter

* indicates required

Follow Us

Subscribe to Blog

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

© Copyright 2024, Baller Alert Inc. All Rights Reserved

No Result
View All Result
  • Home
    • News
    • Entertainment
    • The Baller Alert Show
    • Baller Alert Lists
    • Baller Alert Exclusives
    • Let Me Liv
    • Ballerific Music
    • That’s Baller
    • Fashion
    • Metaverse
    • Tech
    • Lifestyle
    • Sports
    • Op-Ed
    • Travel
    • Health
  • EVENTS
  • Videos
  • Shop
  • About
  • Political News
  • en español
%d